Peptichemio in advanced breast cancer: A clinical evaluation in 32 patients

A. Fornasiero, O. Daniele, V. P. Fosser, A. Paccagnella, L. Salvagno, V. C. Sileni, P. Morandi, M. V. Fiorentino

Research output: Contribution to journalArticlepeer-review


A clinical evaluation of peptichemio (40-45 mg/m2/day for 3 days every 3-4 weeks) was conducted in 32 patients with advanced breast cancer, 28 of whom were evaluable for both toxicity and response. The overall response rate was 18% (one complete remission and four partial remissions), with a median duration of 4 months (range, 2-6). The major side effects were cumulative myelotoxicity, phlebitis, mild nausea, and vomiting. A posttreatment heparin infusion was used to prevent phlebitis.

Original languageEnglish
Pages (from-to)647-649
Number of pages3
JournalCancer Treatment Reports
Issue number5
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Peptichemio in advanced breast cancer: A clinical evaluation in 32 patients'. Together they form a unique fingerprint.

Cite this